Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

The startup is one of several that have recently raised mega rounds of financing to support programs in the clinic or ...

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...

Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered into an in-licensing agreement for an obesity drug with Hansoh ...

Key complementary asset enables synergy and flexibility across Regeneron’s broad pipeline of obesity and metabolic programs focused on improved quality of weight loss, co-morbidities and long ...

In addition, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) revealed plans to license an experimental obesity drug from China’s Hansoh Pharmaceuticals in a deal valued up to $2.01 billion.

Home » Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B . ... Beckley Psytech Ltd. is to be taken over by Atai Life Sciences in an all-share deal that values the U.K. psychedelic drug ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone ... Regeneron's Obesity Trial With Novo Nordisk's Wegovy ... Sanofi Stock Falls After Uneven Smoker’s Lung Drug Data.

Regeneron acquires rights to HS-20094, a promising obesity treatment from Hansoh Pharma, enhancing its metabolic programs. Quiver AI Summary. Regeneron Pharmaceuticals has entered a strategic ...